111 related articles for article (PubMed ID: 25353069)
21. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
[No Abstract] [Full Text] [Related]
22. Buprenorphine maintenance therapy hinders acute pain management in trauma.
Harrington CJ; Zaydfudim V
Am Surg; 2010 Apr; 76(4):397-9. PubMed ID: 20420250
[TBL] [Abstract][Full Text] [Related]
23. Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis.
Zhang H; Kalluri HV; Bastian JR; Chen H; Alshabi A; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2018 Sep; 84(9):2075-2087. PubMed ID: 29873094
[TBL] [Abstract][Full Text] [Related]
24. Precipitated withdrawal in an opioid-dependent outpatient receiving alternate-day buprenorphine dosing.
Jacobs EA; Bickel WK
Addiction; 1999 Jan; 94(1):140-1. PubMed ID: 10665107
[No Abstract] [Full Text] [Related]
25. Complications arising from intravenous buprenorphine abuse.
Seet RC; Oh VM; Lim EC
QJM; 2007 May; 100(5):312-3. PubMed ID: 17456611
[No Abstract] [Full Text] [Related]
26. A Practical Approach for the Management of the Mixed Opioid Agonist-Antagonist Buprenorphine During Acute Pain and Surgery.
Warner NS; Warner MA; Cunningham JL; Gazelka HM; Hooten WM; Kolla BP; Warner DO
Mayo Clin Proc; 2020 Jun; 95(6):1253-1267. PubMed ID: 32061413
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.
Lofwall MR; Wunsch MJ; Nuzzo PA; Walsh SL
J Subst Abuse Treat; 2011 Oct; 41(3):321-9. PubMed ID: 21664789
[TBL] [Abstract][Full Text] [Related]
28. [Necrosis of the glans penis: a complication of an injection of buprenorphin in a opioid abuser].
Hornez E; Laroche J; Monchal T; Bourgouin S; Riviere P; Fournier R; Dantzer E
Ann Chir Plast Esthet; 2010 Apr; 55(2):159-61. PubMed ID: 19269730
[TBL] [Abstract][Full Text] [Related]
29. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose.
Clark NC; Lintzeris N; Muhleisen PJ
Med J Aust; 2002 Feb; 176(4):166-7. PubMed ID: 11913917
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology Update: Probuphine: The Long-Acting Buprenorphine Implant.
Lorman WJ
J Addict Nurs; 2019; 30(2):123-124. PubMed ID: 31162216
[No Abstract] [Full Text] [Related]
31. Blocking endogenous opioids during development--do we understand the consequences?
White J
Addiction; 2013 Feb; 108(2):251-2. PubMed ID: 23331878
[No Abstract] [Full Text] [Related]
32. [Acute poisoning during substitution therapy based on high-dosage buprenorphine. 29 clinical cases--20 fatal cases].
Tracqui A; Tournoud C; Flesch F; Kopferschmitt J; Kintz P; Deveaux M; Ghysel MH; Marquet P; Pépin G; Petit G; Jaeger A; Ludes B
Presse Med; 1998 Mar; 27(12):557-61. PubMed ID: 9767947
[TBL] [Abstract][Full Text] [Related]
33. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
[TBL] [Abstract][Full Text] [Related]
34. The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function.
Shmygalev S; Damm M; Weckbecker K; Berghaus G; Petzke F; Sabatowski R
Drug Alcohol Depend; 2011 Sep; 117(2-3):190-7. PubMed ID: 21353749
[TBL] [Abstract][Full Text] [Related]
35. [Opiate replacement therapy in France: assessment of the public policies].
Chast F
Ann Pharm Fr; 2009 Sep; 67(5):299-303. PubMed ID: 19695365
[No Abstract] [Full Text] [Related]
36. Nicolau syndrome following intramuscular naltrexone injection.
Malik MH; Heaton H; Sloan B
Dermatol Online J; 2020 Jul; 26(7):. PubMed ID: 32898411
[TBL] [Abstract][Full Text] [Related]
37. Buprenorphine prescribing practices and exposures reported to a poison center--Utah, 2002-2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(49):997-1001. PubMed ID: 23235296
[TBL] [Abstract][Full Text] [Related]
38. [Naltrexone and opiate substitutive treatment].
Dupouy J; Poutrain JC; Lapeyre-Mestre M
Therapie; 2011; 66(6):549-52. PubMed ID: 22691393
[No Abstract] [Full Text] [Related]
39. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
Douglas Bruce R; Moody DE; Chodkowski D; Andrews L; Fang WB; Morrison J; Parsons TL; Friedland GH
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):80-5. PubMed ID: 23421567
[TBL] [Abstract][Full Text] [Related]
40. Opioid-related mortality and filled prescriptions for buprenorphine and methadone.
Wikner BN; Öhman I; Seldén T; Druid H; Brandt L; Kieler H
Drug Alcohol Rev; 2014 Sep; 33(5):491-8. PubMed ID: 24735085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
